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Introduction
Since its original description in the 1930s, use of the 
term “atypical pneumonia” has been refined from “any 
community-acquired pneumonia (CAP) that is different to 
that caused by Streptococcus pneumoniae”, to indicate 
“a CAP caused by one of several identified pathogens 
including Legionella pneumophilia, Mycoplasma 
pneumoniae, Chlamydophila pneumoniae, and Coxiella 
burnetti”. More recently, some authors have included 
new pathogens, such as avian influenza and the severe 
acute respiratory syndrome (SARS) virus. This, and the 
awareness of a greater overlap in the clinical presentation 
between “typical” and “atypical” pathogens, has raised 
questions around the validity and utility of the term “atypical 
pneumonia”. Murdoch and Chambers have advocated 
that atypical pneumonia be restricted to “pneumonia that 
is unusual in clinical presentation, epidemiology, or both”, 
a definition that would help in identifying new trends in 
incidence, outbreaks, and recognition of novel respiratory 
pathogens.1 This review will focus on traditional atypical 
pathogens, as well as highlight other important organisms 
in the southern African context.
Epidemiology
Atypical pneumonia caused by L. pneumophilia, M. pneu-
moniae, C. pneumoniae or C. burnetti, accounts for 8-63% 
of all cases of CAP worldwide, depending on the geographi-
cal location of the study, whether it is community or hospital 
based, and the type of cohort, i.e. general ward vs. intensive 
care unit (ICU) admission.2 
Few studies have reported on the incidence of atypical 
pathogens causing CAP in southern Africa, and those 
that have, have mostly originated from South Africa. None 
of these studies were carried out in community cohorts. 
Limited financial resources, lack of sampling, and the 
predominant reliance on serology for diagnosis, has 
hampered epidemiological studies. 
In-patient studies from South Africa suggest that the 
prevalence of atypical pathogens causing CAP ranges 
from 1-36%.3-6 M. pneumoniae caused 10% of CAP in 
81 in-patients admitted to Tygerberg Hospital.3 Another 
prospective serological study of 92 consecutive patients 
admitted to Groote Schuur Hospital, Cape Town, with CAP, 
found 36% to be infected with an atypical pathogen, 20.7% 
with C. pneumoniae, 8.7% with L. pneumophilia, and 1.1% 
with M. pneumoniae.4 Elsewhere in South Africa, a study 
from KwaZulu-Natal found 21% of isolates in patients with 
CAP to be due to atypical pathogens. M. pneumoniae, 
C. pneumonia, and L. Pneumophilia, accounted for 13%, 
8% and 1% respectively.5 Lastly, in an 11-year retrospective 
review of 259 patients admitted to the Hillbrow Hospital ICU 
in Johannesburg with severe CAP, of the 26 patients who 
had Legionella and Mycoplasma serology, sent on suspicion 
of an atypical pneumonia, two patients were diagnosed 
with M. pneumoniae and one with L. pneumophilia.6 Taken 
together, these studies suggest that, although the rate of 
atypical pneumonia in hospitalised adults in South Africa 
may be as high as one-third of all CAP, their contribution to 
severe disease requiring ICU admission, may be minimal. 
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Further ICU studies in different locations are required 
to confirm this suspicion. Furthermore, the incidence of 
M. pneumoniae requiring ICU is likely to vary in a cyclical 
manner, in line with its epidemic cycles.
Legionellosis is not only a community-acquired infection. 
There have been over 300 reports of outbreaks of hospital-
acquired legionellosis worldwide, the largest having occurred 
in a veterans administration hospital in Los Angeles, with 
218 confirmed cases between 1977-1982.7 In South Africa, 
a number of small outbreaks have been recorded, including 
an outbreak at a Johannesburg teaching hospital, in which 
two of 12 cases were hospital acquired.8 The vast majority 
of hospital-acquired Legionnaires’ disease outbreaks are 
not due to water cooling towers or air conditioning units, 
as previously thought, but rather to potable water supplies 
within the hospital.9,10 Obtaining routine environmental 
cultures of hospital water supplies is an effective strategy 
for the prevention of hospital-acquired legionellosis, yet 
this practice is seldom carried out. Rather, the approach of 
the Centers for Disease Control and Prevention (CDC) of 
using environmental cultures, only in the event of discovery 
of cases of hospital-acquired infections, is adopted.11 
Not surprisingly, studies show that if the water supply is 
known to be colonised with Legionella, hospital-acquired 
legionellosis can be found, if proper surveillance and 
laboratory testing of all patients with hospital-acquired 
pneumonia is undertaken. With the financial implications 
that this would have in the state sector in southern Africa, 
such screening is not, and will not, be undertaken. However, 
it has important implications for the choice of empiric 
antibiotic therapy for hospital-acquired infections. 
Although not traditionally regarded as an atypical 
pathogen, nor a predominant pathogen, in adults, the 
clinical presentation and increasing incidence of Bordatella 
pertussis needs to be recognised in adults presenting 
with CAP. Classically an infection of children, respiratory 
symptoms in adults more often lack the characteristic 
whoop seen in young children, and presents as a prolonged 
cough that commonly continues for more than two weeks. 
Unlike tuberculosis, which would be the predominant 
differential diagnosis of a chronic cough in southern Africa, 
pertussis rarely presents with the classic constitutional 
symptoms associated with Mycobacterium tuberculosis 
infection. Approximately 17% of cases of pertussis reported 
in South Africa between 1998-2002 were seen in adults.12 
Interestingly, a rising incidence in age distribution has 
been seen in some countries outside of southern Africa, 
with 12-32% of cases of a cough lasting longer than two 
weeks in Australia, being due to pertussis.13 Due to a lack 
of awareness and missed opportunities for diagnosis in 
resource-limited settings such as southern Africa, the true 
incidence of pertussis in adults presenting with a prolonged 
cough is unknown. However, with the heavy burden of 
tuberculosis, and the increasing use of empirical therapy 
in smear negative pulmonary tuberculosis, it is likely that a 
substantial number of cases is being missed. Treatment with 
a macrolide reduces the duration and severity of symptoms, 
and transmissibility.14 
Despite the introduction of antiretroviral therapy, human 
immunodeficiency virus (HIV) remains a risk factor for 
CAP, with increased nasopharyngeal colonisation by 
S. pneumonia,15 and an association with cigarette 
smoking.16 There is an inverse correlation between risk 
of CAP and cluster of differentiation 4 T (CD4) cell count, 
although introduction of antiretroviral treatment (ART) does 
reduce the incidence of CAP, even at CD4 counts of up 
to 500 cells/mm.3,17,18 An aetiological diagnosis is made in 
approximately one-third of HIV-infected patients with CAP,17 
and it would seem from the limited studies elsewhere in the 
world to date, that the incidence of atypical pathogens is 
low. Two studies from Spain found that Legionella infections 
were particularly uncommon,19,20 and it is hypothesised that 
this may be due to the intrinsic activity of cotrimoxazole 
against L. pneumophilia. Cotrimoxazole is used as primary 
prophylaxis in HIV patients.21 A further study from Spain 
found no difference in clinical features between HIV-infected 
and uninfected patients with legionellosis.22 
Clinical presentation of atypical 
pneumonias
The incubation period for atypical pathogens varies from two 
to 21 days. None of the clinical features common to atypical 
pneumonias, including fever, a cough (dry or productive) 
and myalgia, are unique to atypical pathogens. However, the 
presence of extra-pulmonary features is common, including 
cardiac, neurological, dermatological, musculoskeletal, 
renal and haematological features. C. burnetti and 
L. pneumophilia infection are more commonly associated 
with headache, confusion (rare with M. pneumoniae), 
and pleuritic chest pain. In addition, abdominal pain and 
diarrhoea are more commonly reported in L. pneumophilia 
infections.23 
Respiratory signs, e.g. crepitations, may be minimal or 
absent. Relative bradycardia has been associated with 
L. pneumophilia and C. burnetti, although this sign is 
more commonly absent. Splenomegaly may be a feature 
of Q fever due to C. burnetti. Radiographic findings are 
often non-specific, and could include patchy infiltrates, 
consolidation, circumscribed lesions, or round infiltrates 
and pleural effusions, the latter having been described 
in association with C. burnetti, M. pneumoniae and 
L. pneumophilia. Hilar adenopathy and cavitation have been 
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identified in immunocompromised patients,24 which in the 
southern African context evokes the differential diagnosis 
of tuberculosis in HIV-infected patients. 
Table I describes individual characteristics of the atypical 
pneumonias.
Diagnosis 
Historically, the diagnosis of atypical pathogens, as a cause 
of CAP, has relied on demonstrating a serological response 
in acute and convalescent blood samples, as the fastidious 
nature of the organisms makes culture difficult. Outside 
of trial conditions, the loss to follow-up rate is such that 
convalescent serology is rarely sent, and, in the context of 
southern Africa, it remains an expensive and impractical 
test. Approximately 85% of cases of Legionnaires’ disease 
are due to L. pneumophilia subtype 1, which is the target 
for the Legionella urinary antigen test. Although relatively 
simple to use, in practical terms, this test is rarely used in 
southern Africa due to resource limitations, and the fact that 
the test’s sensitivity reduces with the time from symptom 
onset, with late presentation being common in our setting. 
Molecular tools are a promising advance for the diagnosis 
of bacterial (including atypical pathogens), and viral, causes 
of pneumonia. A full description of molecular diagnostics is 
outside the scope of this review, but real-time polymerase 
chain reaction (PCR) on sputum is perhaps the most 
promising advance to date.27 
Treatment 
International and society-generated guidelines for the 
treatment of CAP differ subtly in their emphasis on the place 
of antibiotics that cover atypical pathogens with regard to 
the regimen and the timing of their introduction. 
Macrolides, or the azalide azithromycin, are the major class 
of antibiotics used to treat proven or suspected atypical 
infections, although the ketolide telithromycin, doxycycline, 
and a number of fluoroquinolones, are also known to be 
active. The use of fluoroquinolones in areas with a high 
prevalence of tuberculosis in southern Africa should be 
discouraged, due to their anti-mycobacterial action. If 
tuberculosis was present, either as the primary diagnosis, 
or as a co-infection, monotherapy with a fluoroquinolone, 
may lead to rapid resistance of the mycobacterium. 
Whether anti-atypical cover is given orally or parenterally, 
as monotherapy or in combination with a β-lactam or other 
antibiotic, will depend on the known resistance patterns for 
common causes of CAP in a particular region or institution, 
and the severity of infection. The standard severity of illness 
score used to assess patients with CAP is the Confusion, 
Urea, Respiratory rate, Blood pressure (CURB)-65 score 
(Table II), which is easy to use, and correlates with more 
complex scoring systems. 
Table II: CURB-65 score for severity of illness
Variable CURB-65 score and interpretation
Confusion (C) 0-1: Mild community-acquired 
pneumonia, potentially suitable for 
home care.
 2: Moderately ill, observe in hospital 
initially.
> 3: Severe community-acquired 
pneumonia. Consider admission to 
high care unit, or intensive care unit. 
Urea ≥ 7 mmol/l (U)
Respiratory rate ≥ 30 bpm (R)
Low blood pressure: systolic  
< 90 mmHg and diastolic  
≤ 60 mmHg (B)
Age ≥ 65 years (65)
As it may not be possible to measure urea, an abbreviated 
CRB-65, based solely on clinical criteria, may also be 
used. A score of 0 indicates a very low mortality risk, and 
does not require hospitalisation. Hospitalisation should be 
Table I: Characteristics of atypical pneumonias
Mycoplasma pneumoniae Legionella pneumophilia Chlamydophilia pneumoniae Coxiella burnetti
Microbiological
characteristics
Fastidious, difficult to grow in 
the laboratory






Risk groups Children or young adults (5-25 
years old).
Cyclical epidemics occur every 
three to five years.
Elderly with co-morbidities 
and immune-compromised 
individuals.
Sporadic infection or outbreaks 
are associated with water 
aerosols.
Asthmatics and patients with 
cardiovascular disease25 
Exposure to contaminated body 
fluids of infected cattle, goats 
and sheep (farmers, abattoir 
workers, vets).
Endocarditis risk in patients with 
pre-existing valve lesions.13
Diagnostic tests Acute and convalescent 
serology.
Cold agglutinins (poor 
sensitivity and specificity).
Real-time PCR.
Direct isolation on specialised 
media rarely used.
Acute and convalescent 
serology (IFA or ELISA).
Urinary antigen (subgroup 1) in 
first 7-10 days of symptoms.
Direct isolation on specialised 
media rarely used.
Fourfold increase in IgG three 
weeks apart, or a single IgM 
titre ≥ 1:64.26
Cell culture and PCR not 
routinely available.
Acute and convalescent 
serology.
Isolation of the organism 
requires biosafety 3 facility
PCR from sputum.
Antibiotics used in 
management
Macrolides, azalides, doxycycline or fluoroquinolones are active
PCR: polymerase chain reaction, IFA: immunofluorescent assay, ELISA: enzyme-linked immunosorbant assay, IgG: immunoglobulin G, IgM: immunoglobulin M
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considered for a score of 1-2, and any person with a CRB-
65 score of 3 or 4 requires urgent hospitalisation. 
The current South African guidelines for the management 
of CAP in adults were published by a working group of the 
South African Thoracic Society in 2007.28 
Although it is suggested in the document that the incidence 
of atypical pathogens as a cause of CAP in South Africa is 
low, the guidelines recommend the use of antibiotics that 
cover atypical pathogens in the following situations:
•	 As monotherapy for a proven atypical pathogen, or as 
combination therapy for any patient with a suspected 
atypical pathogen. Due to the increasing resistance 
profile of S. pneumoniae to macrolides or azalides in 
South Africa, monotherapy with a macrolide or azalide is 
not recommended in cases where the cause of the CAP 
is not proven to be due to an atypical pathogen. 
•	 As there is emerging evidence of the benefit of 
combination therapy for severely-ill patients who are 
admitted to hospital with CAP, a macrolide is indicated 
in combination with a β-lactam. Hence all patients with 
CURB-65 of ≥ 3 should receive an intravenous macrolide 
or azalide, or fluoroquinolone with a β-lactam. 
The South African guidelines share some similarities with 
international guidelines, such as the joint Infectious Diseases 
Sociey of America (IDSA)/American Thoracic Society 
(ATS) guidelines from North America29 and the European 
guidelines.30 In keeping with the American guidelines, 
the South African guidelines also advocate β-lactam and 
macrolide combinations for patients admitted to hospital 
who do not require ICU management, or in combination 
with a β-lactam and aminoglycoside in ICU patients. In 
out-patient treatment settings, macrolide monotherapy is 
also advocated, but unlike the South African guidelines, 
this includes treatment for patients in whom an atypical 
pathogen is not confirmed. However, if the patient has co-
morbidities, it is necessary to revert to the combination 
of a β-lactam and macrolide. The European guidelines, 
published in 2005, echo much of what is recommended in 
the joint American guidelines, although outpatient treatment 
of CAP with amoxicillin, or a tetracycline, is preferred over 
a macrolide.30 
Furthermore, a greater emphasis is put on differentiating 
between patients with acute exacerbations of chronic 
obstructive pulmonary disease, and those with CAP.
Caution should be adopted when choosing macrolide 
or azalide cover for HIV-infected patients on ART. 
Azithromycin is preferred over clarithromycin for patients 
on a non-nucleoside reverse transcriptase inhibitor, such 
as nevirapine or efavirenz, due to significant drug-drug 
interactions.31 
One omission from the South African guidelines is a 
discussion of the use of neuraminidase inhibitors for 
suspected influenza infection, either as a primary cause 
of pneumonia, or as a co-infecting pathogen. Both 
the American and European guidelines advocate early 
oseltamivir or zanamivir for patients suspected of having 
influenza. As this infection is seasonal outside of a 
pandemic situation, we would advocate the immediate 
use of oseltamivir in any patient admitted to hospital with 
serious CAP during the influenza season, and would have 
a very high index of suspicion for influenza as a diagnosis, 
or co-infecting organism, in any person with severe acute 
respiratory illness in the months before the usual median 
onset of the influenza season, which for South Africa is 
week 23, i.e. the second week in June. This is in line with 
the guidelines of the National Institute for Communicable 
Diseases (NICD) on influenza.32
Conclusion
A lack of studies defining the burden of atypical pathogens 
causing pneumonia in the community setting undermines 
our ability to determine optimal antibiotic guidelines for CAP. 
The perception that atypical pathogens are a rare cause 
of CAP, is not necessarily borne out by in-patient studies, 
which suggest that up to 30% of cases are due to these 
organisms in patients not requiring ICU. A large community-
based national study of the incidence of atypical pneumonia 
would help considerably towards rationalising our approach 
to these atypical pathogens, and further ICU-based studies 
would also be of benefit. 
Lack of reliable, point-of-care tests hampers diagnosis, and 
requires the use of combination antibiotics that include a 
macrolide or fluoroquinolone. Unfortunately, this can only 
drive macrolide resistance, and in private practice, where 
a greater amount of fluoroquinolones are prescribed as 
empiric therapy for CAP, drive fluoroquinolone resistance in 
M. tuberculosis, threatening the tuberculosis programme. 
Such prescribing should be discouraged vigorously. 
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